Logo Coronavir.org

Coronavir.org

Site de veille et d'information sur le nouveau coronavirus SARS-COV-2 et la maladie associée COVID-19

Actualités et recherches en cours

In October, 2021, WHO estimated that—because of the COVID-19 pandemic—global deaths from tuberculosis had increased for the first time in a decade.1 This estimate of increased mortality has been widely interpreted as an objective fact.2 But it is important to point out a footnote published with these estimates: “To estimate the impact [of COVID-19 on tuberculosis]…models were developed for…16 countries…and a statistical model was used to extrapol...

Researchers expect T cells generated by vaccination or COVID-19 infection to be effective against the omicron (B.1.1.529) variant. They analysed more than 1500 epitopes, fragments of SARS-CoV-2's viral proteins, that were recognised by T cells in COVID-19 patients or after vaccination and found that omicron was unlikely to evade such T cells. The study reported that only 20% of virus epitopes showed mutations associated with omicron. When the res...

In the present study, serum samples of 20 hospitalized COVID-19 patients from Brazil who were infected by the earlier SARS-CoV-2 lineages B.1.1.28 and B.1.1.33, and by the variant of concern (VOC) Gamma (P.1) were tested by plaque reduction neutralization test (PRNT90) with wild isolates of a panel of SARS-CoV-2 lineages, including B.1, Zeta, N.10, and the VOCs Gamma, Alpha, and Delta that emerged in different timeframes of the pandemic. The mai...

Successive waves of infection by SARS-CoV-2 have left little doubt that this virus will transition to an endemic disease 1,2. Projections of the endemic seasonality of SARS-CoV-2 transmission are crucial to informed public health policy 3. Such projections are not only essential to well-timed interventions and the preparation of healthcare systems for synchronous surges with other respiratory viruses 4, but also to the elimination of seasonality...

Background A SARS-CoV-2 vaccine booster dose has been recommended for all nursing home residents. However, we lack effectiveness data on boosters preventing infection, death and hospitalization in this frail population. Methods We emulated nested target trials in two large nursing home systems in parallel to evaluate the effectiveness of a SARS-CoV-2 mRNA vaccine booster at preventing infection, hospitalization, or death. Residents who completed...

Immunocompromised patients are particularly susceptible to serious complications from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Two mRNA vaccines, BNT162b2 and mRNA-1273, have been shown to have excellent clinical efficacy in immunocompetent adults, but diminished activity in immunocompromised patients. In this study, we measured anti-spike SARS-CoV-2 antibody response, avidity, and surrogate neutralizing antib...

Abstract Background The Omicron variant of SARS-CoV-2 infection poses substantial challenges to public health. In England, "plan B" mitigation measures were introduced in December 2021 including increased home working and face coverings in shops, but stopped short of restrictions on social contacts. The impact of voluntary risk mitigation behaviours on future SARS-CoV-2 burden is unknown. Methods We developed a rapid online survey of risk mitiga...

Background: Vaccines have emerged as a crucial tool in combatting the COVID-19 pandemic particularly those based on SARS-CoV-2 S-protein mRNA. A crucial aspect of vaccine efficacy is the duration of antibody responses. In this study, a seroconversion panel was created to assess antibody responses to the mRNA-1273 vaccine over time (6.5 months). Methods: Blood samples collected from 15 healthy adult participants prior to and up to 6.5 months afte...

Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose SARS-CoV-2 mRNA series, the FDA approved a booster dose for people greater than 12 years old. Limited data exist on whether a booster dose of the mRNA vaccine results in greater antibody protection than the primary series. We examined total and neutralizing antibodies to the spike protein of SARS-CoV-2, and neutralizing antibodies against Washington-1 (WA-1) and...

Background The increase in SARS-CoV-2 infections in December 2021 in the United States was driven primarily by the Omicron variant which largely displaced the Delta over a three week span. Outcomes from infection with the Omicron remain uncertain. We evaluate whether clinical outcomes and viral loads differ between Delta and Omicron infections during the period when both variants were co-circulating. Methods Remnant clinical specimens from patie...

Important : Le contenu diffusé sur Coronavir.org ne doit jamais remplacer les conseils d'un médecin ou des autorités de santé locales.